Cornea research for understanding the pathogenesis of disease

In our research group, we investigate mechanisms leading to blinding pathologies of the cornea at the molecular, gene- and tissue level.

We also use the cornea as an experimental model to gain insights into neovascular disease (angiogenesis). New regenerative treatments and surgical techniques are being researched and developed, and patient populations are being characterized in clinical studies using advanced imaging techniques. Some of the ongoing projects in the group include:

  • Mechanisms and treatment of corneal neovascularization
  • Non-invasive imaging of peripheral nerve fibers in the cornea as a surrogate marker for diabetes onset and progression
  • Clinical, molecular and genetic studies of European aniridia cohorts
  • Bioengineering the cornea: from materials to clinical applications

 

EU COST Action CA18116 – Aniridia: networking to address an unmet medical, scientific, and societal challenge (ANIRIDIA-NET), 2019 – 2023

Action Coordinator and Main Proposer: Neil Lagali

Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual's lifetime. A congenital genetic mutation causes an underdeveloped retina, cataract, glaucoma, and a progressive ocular surface disease of stem cell deficiency and loss of corneal transparency. Classified as a rare disease (ORPHA:77), aniridia is extremely challenging for the ophthalmologist, with very few effective treatments available. This stems from a lack of adequate-sized patient populations to conduct coordinated clinical and research activities, and a lack of information exchange in assessing and treating aniridia, with expertise typically limited to geographically-dispersed centers. The goals of ANIRIDIA-NET are therefore to:

  1. Build a large, inclusive EU network of ophthalmologists, scientists, trainees, aniridia patient organizations, industry, and special interest groups to create linkages and a rich training ground for a new generation of trainees;
  2. Improve aniridia management through evidence-based research, harmonized clinical protocols, pooling/sharing of samples and models, and consensus activities; and
  3. Stimulate development of novel diagnostics and treatments for aniridia based on innovative research in regenerative medicine/stem cells, investigational drugs, gene therapy, tissue engineering, transplantation, etc.

 

Although a rare disease, aniridia is associated with ocular surface pathology such as dry eye, inflammation, stem cell insufficiency, nerve degeneration, and vascularization - problems common to many ocular surface pathologies collectively affecting large populations. Greater collaboration and sharing of information and resources in the area of aniridia is therefore additionally expected to have significant benefits for the treatment of larger patient populations with ocular surface disease.

 

EU Horizon2020 RIA Project: Advanced Regenerative and Restorative Therapies to Combat Corneal Blindness (ARREST BLINDNESS), 2016 – 2020

Project Coordinator: Neil Lagali

ARREST BLINDNESS is a consortium of 13 institutions in 8 countires, performing a four-year research project funded by the HORIZON 2020 program of the European Commission. Within the project we are developing and validating advanced regenerative and restorative therapies to treat the loss of corneal transparancy so that it does not result in blindness.

Read more: www.arrestblindness.eu

COST BM1302

Joining Forces in Corneal Regeneration Research, project time 2013-2017.

Publications

Research

Organisation